Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
O60662
UPID:
KLH41_HUMAN
Alternative names:
Kel-like protein 23; Kelch repeat and BTB domain-containing protein 10; Kelch-related protein 1; Sarcosin
Alternative UPACC:
O60662; Q53R42
Background:
Kelch-like protein 41, also known as Kel-like protein 23, Kelch repeat and BTB domain-containing protein 10, Kelch-related protein 1, and Sarcosin, plays a pivotal role in skeletal muscle development and differentiation. It is instrumental in the regulation of myoblast proliferation and differentiation, contributing to myofibril assembly by promoting the lateral fusion of thin fibrils into mature, wide myofibrils. This protein is essential for pseudopod elongation in transformed cells.
Therapeutic significance:
Kelch-like protein 41 is linked to Nemaline myopathy 9, a muscular disorder characterized by muscle weakness and abnormal structures in muscle fibers. Understanding the role of Kelch-like protein 41 could open doors to potential therapeutic strategies for treating this condition, highlighting its importance in muscle pathology and offering a promising avenue for drug discovery.